Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Multiple Myeloma Gammopathies

Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Comparison of survivals for the two periods (2005-2009 and 2010–2014).


  1. 1.

    Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–60.

    CAS  Article  Google Scholar 

  2. 2.

    Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380:2104–15.

    CAS  Article  Google Scholar 

  3. 3.

    Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a Randomised, Open-Label, Phase 3 Trial. Lancet. 2020;395:132–41.

    CAS  Article  Google Scholar 

  4. 4.

    Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a Randomised, Open-Label, Phase 3 Study. Lancet. 2019;394:29–38.

    CAS  Article  Google Scholar 

  5. 5.

    Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132:2456–64.

    CAS  Article  Google Scholar 

  6. 6.

    Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldshmidt H, Lentzsch S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28:269–77.

    CAS  Article  Google Scholar 

  7. 7.

    Mohty M, Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, et al. Multiple myeloma treatment in real-world clinical practice: results of a Prospective, Multinational, Noninterventional Study. Leukemia. 2018;32:1542–60.

    Article  Google Scholar 

  8. 8.

    Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–20.

    CAS  Article  Google Scholar 

  9. 9.

    Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371:906–17.

    CAS  Article  Google Scholar 

Download references


The authors would like to thank the Intergroupe Francophone du Myélome for providing patient samples and clinical data. This work was supported by National Institutes of Health, National Cancer Institute Grants PO1-155258 and P50-100707 (HA-L) and the Cancer Pharmacology of Toulouse and Region (CAPTOR) program. The Centre de Recherches en Cancérologie de Toulouse Team 13 is supported by the Fondation ARC (Association pour la Recherche sur la Cancer, grant PGA1*20160203788).

Author information




Corresponding author

Correspondence to Hervé Avet-loiseau.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Corre, J., Perrot, A., Hulin, C. et al. Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods. Leukemia (2021).

Download citation


Quick links